It has been shown by Sun et al. that QHD reduces hepatic lipid accumulation through the JAK2/STAT3/CPT-1 A-related fatty acid β-oxidation pathway, thus treating non-alcoholic steatohepatitis (NASH) [15]. The gene discussed is JAK2; the disease is metabolic dysfunction-associated steatohepatitis.